Clinical Trial Update: Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of temozolomide, procarbazine, and cilengitide in newly diagnosed MGMT unmethylated glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• MATULANE (Procarbazine hydrochloride)
• Temodar (Temozolomide)
• cilengitide (cilengitide)

Snippet

Sponsor: Northern Sydney and Central Coast Area Health Service | Conditions: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 | Phase 2 | Status: UNKNOWN